Need Support? Freefone 24 hour helpline UK 080 8800 3344 Rep of Ireland 1800 41 33 44

News & media

News

Back to News Archive

Meningitis warning for returning Hajj pilgrims

09 February 2004

Meningitis Research Foundation is reminding returning Hajj pilgrims and their families of the symptoms of meningitis and septicaemia, as over the last few years there have been cases of these diseases following the Hajj.

Although there are vaccines which give excellent protection against meningitis and septicaemia (blood poisoning) they cannot protect against all forms. Therefore it is important that if someone becomes ill, symptoms are recognised quickly and medical help obtained immediately.

These diseases often start with flu-like symptoms - fever, vomiting, cold hands and feet, shivering and joint and muscle pain. Severe headache, stiff neck and dislike of bright lights may also be present as well as a rash which could appear anywhere on the body.

Linda Glennie, Meningitis Research Foundation's Head of Research and Medical Information, commented: "In view of the outbreaks of meningitis and septicaemia over the past few years associated with the Hajj, it is important that pilgrims and their families are aware of the symptoms. With these diseases, the quicker they are diagnosed and treated, the better the chances for a good recovery."

Further information about meningitis and septicaemia can be obtained from Meningitis Research Foundation's Freefone 24 hour helpline - 080 8800 3344.

Information, written and audio, is available in 18 languages including Arabic, Bengali, Gujarati, Punjabi, Somali, Turkish and Urdu by contacting the Foundation or through this website. An interpreter service in 120 languages is also available via the helpline.

What progress is being made?

Since it was founded in 1989, the charity has awarded 122 research grants, leading to many advances in the prevention, detection and treatment of meningitis and septicaemia. The total value of the Foundation's investment in vital scientific research is nearly £13.5/€19 million.

 

Find out more about our programme of research.